SAN FRANCISCO--(BUSINESS WIRE)--Enlitic, a privately-held company utilizing artificial intelligence to streamline medical imaging workflows for radiologists, announced the close of its $15M Series B financing round. The investment was led by Marubeni, with whom the company has been developing the Japanese market since 2017. The round saw further investment from Capitol Health, who previously led the company's Series A in 2016, as well as new participation from several top investors in Australia. Approximately 10% of the round was set aside for individual radiologists and other physicians who have either trained or used the company’s medical AI solutions. Enlitic plans to use the funding to enhance its artificial intelligence product portfolio, expand its engineering and data scientist teams, and focus on regulatory approval for clinical use in the US, Australia, Japan, Europe, Canada, and Brazil.
Kevin Lyman, CEO of Enlitic, commented, “Radiologists have one of the hardest jobs in the world. They need to be able to identify thousands of different abnormalities in hundreds of different types of images. Even a single mistake can mean life or death, and yet they’re asked to read under tremendous time pressure in an environment full of distractions. Our Series B is a huge step toward helping them relieve this pressure and improve patient outcomes. We are incredibly grateful for the support of our partners, including Marubeni and Capitol Health, and look forward to continuing our work with them to build meaningful diagnostic solutions.”
Enlitic uses deep learning and other forms of artificial intelligence to develop algorithms that identify and analyze suspicious findings in medical images. Working closely with hospitals and radiology providers around the world, the company has developed a comprehensive platform enabling the development, validation, and seamless integration of clinical AI at scale. Early applications of Enlitic’s technology were shown to speed up radiologist’s interpretation by over 20%, while improving true positive rates and reducing false positive rates by over 10%. Other applications were shown to assist in the identification of malignancy up to two years earlier.
Radiologist Dr. Anthony Upton, Chief Medical Officer at Enlitic, remarked, “Closing this round is a significant advancement to help Enlitic achieve its ambitious strategy to make meaningful clinical products for radiology and the associated healthcare markets. This will allow Enlitic to scale production towards achieving AI models that cover the entire body, which will offer a significant impact to daily clinical workflows.”
Enlitic’s first product interprets chest x-rays, triaging normal from abnormal scans, and detecting and characterizing more than 40 distinct abnormalities such as cardiomegaly, lung nodules, and pneumothorax. Chest x-rays are notoriously difficult to interpret given the image’s lack of specificity, yet they are still the most common type of radiological examination, representing an estimated 45% of all studies globally. Enlitic is working with partners around the world for the relevant approvals to deploy this product in several countries, helping radiologists to interpret chest x-rays faster, and with higher accuracy.
Recognizing the massive complexity of the average diagnostic workflow, Enlitic is rapidly training models to assist in more areas of radiology. In January of this year, the company launched their new datacenter with a GPU supercluster enabling model development at more than 10x the speed. In February, they launched their global beta program, enabling their models to be regionally tuned and tested in several countries simultaneously. At their current pace, Enlitic expects to be able to interpret 95% of all types of x-rays by the end of 2019, and 95% of common CTs and MRIs by 2021.
Marubeni, who led the Series B investment round, is a Japanese trading company and one of the largest sogo shosha, (general trading companies), with 12 business divisions. Marubeni is a key partner to Enlitic and will help drive development and adoption of Enlitic’s products in Japan. Marubeni added, “Japan especially suffers from an aging population and a shrinking birth rate, placing an increasing burden on hospitals and radiologists. With Enlitic’s groundbreaking AI products, we see a way to accurately and efficiently address our current healthcare challenges in Japan and Asia, while providing superior healthcare.”
Enlitic Inc. is a pioneer in medical deep learning that leverages its proprietary algorithms to quickly and accurately improve healthcare diagnosis. With a platform developed by renowned data scientists, machine learning practitioners, and medical experts, Enlitic is able to analyze a wide variety of healthcare data sources, including billions of clinical cases, to improve diagnostic accuracy, speed and patient outcomes, as well as accelerate pharmaceutical research and drug trials. Named one of the world’s “50 Smartest Companies” by MIT Tech Review, Enlitic is based in San Francisco and serves customers around the world. For more information, please visit us April 12-14 at the International Technical Exhibition of Medical Imaging Conference (ITEM) at booth #A001. Find out more at www.enlitic.com, and follow us on Twitter, and Linkedin.
Marubeni is a major Japanese integrated trading and investment business conglomerate that handles products and provides services in a broad range of sectors. Marubeni is set on globally collaborating with technology-driven medical solution providers as well as savvy medical partners with our vision of building the digital healthcare platform for a comprehensive prophylaxis and diagnosis services using AI.
About Capitol Health
Capitol Health is a leading provider of diagnostic imaging and related services to the Australian healthcare market. Headquartered in Melbourne, Victoria, the Company owns and operates clinics throughout Victoria. The Company’s operational focus is on delivering a community-based infrastructure for radiologists and related medical practitioners to deliver optimal, efficient, accurate healthcare service outcomes for patients.